We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLCT
2601
DELISTED
Select Bancorp, Inc.
SLCT
| $293K | ﹤0.01% |
23,844
-209
| -0.9% | -$2.46K |
|
2602
C&F Financial
CFFI
$273M
| $292K | ﹤0.01% |
5,277
-24
| -0.5% | -$1.28K |
|
2603
Standard BioTools
LAB
$339M
| $292K | ﹤0.01% |
83,821
-225
| -0.3% | -$791 |
|
2604
Progyny
PGNY
$2.47B
| $292K | ﹤0.01% |
+10,620
| New | +$255K |
|
|
BRT
2605
BRT Apartments
BRT
$282M
| $291K | ﹤0.01% |
17,140
+181
| +1% | +$3.04K |
|
|
CMLS
2606
DELISTED
Cumulus Media Inc. Class A Common Stock
CMLS
| $291K | ﹤0.01% |
16,576
+300
| +2% | +$4.6K |
|
|
ESXB
2607
DELISTED
Community Bankers Trust Corporation
ESXB
| $291K | ﹤0.01% |
32,735
-100
| -0.3% | -$867 |
|
|
BOCH
2608
DELISTED
Bank of Commerce Holdings (CA)
BOCH
| $291K | ﹤0.01% |
25,189
+5
| +0% | +$57 |
|
2609
Bankwell Financial Group
BWFG
$538M
| $290K | ﹤0.01% |
10,053
-30
| -0.3% | -$857 |
|
|
ONIT
2610
Onity Group
ONIT
$319M
| $290K | ﹤0.01% |
14,101
+75
| +0.5% | +$1.81K |
|
2611
Cadiz
CDZI
$260M
| $289K | ﹤0.01% |
26,236
-182
| -0.7% | -$2.1K |
|
2612
Culp Inc
CULP
$44.2M
| $289K | ﹤0.01% |
21,218
+2,831
| +15% | +$43.5K |
|
2613
Preformed Line Products
PLPC
$2.07B
| $289K | ﹤0.01% |
4,791
+12
| +0.3% | +$747 |
|
2614
Ribbon Communications
RBBN
$379M
| $289K | ﹤0.01% |
93,252
+425
| +0.5% | +$1.69K |
|
|
SPNE
2615
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $289K | ﹤0.01% |
24,102
| – | – |
|
|
AKCA
2616
DELISTED
Akcea Therapeutics Inc
AKCA
| $288K | ﹤0.01% |
17,024
+184
| +1% | +$3.42K |
|
2617
Spyre Therapeutics
SYRE
$8.24B
| $286K | ﹤0.01% |
1,499
+7
| +0.5% | +$1.37K |
|
|
RYZ
2618
Ryerson Holding Corp
RYZ
$1.46B
| $285K | ﹤0.01% |
24,098
+1,209
| +5% | +$11.9K |
|
|
BBBY
2619
Bed Bath & Beyond
BBBY
$507M
| $284K | ﹤0.01% |
53,651
-183
| -0.3% | -$1.23K |
|
2620
Pure Cycle
PCYO
$258M
| $284K | ﹤0.01% |
22,588
-17
| -0.1% | -$199 |
|
|
PHX
2621
DELISTED
PHX Minerals
PHX
| $284K | ﹤0.01% |
25,354
+426
| +2% | +$5.59K |
|
2622
Rafael Holdings
RFL
$104M
| $284K | ﹤0.01% |
16,114
+273
| +2% | +$4.97K |
|
2623
Construction Partners
ROAD
$6.11B
| $284K | ﹤0.01% |
16,814
+5,569
| +50% | +$97.8K |
|
2624
Weyco Group
WEYS
$385M
| $284K | ﹤0.01% |
10,733
-18
| -0.2% | -$445 |
|
|
BFYT
2625
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
| $284K | ﹤0.01% |
14,742
+111
| +0.8% | +$2.51K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.